Strategic Partnerships NuvOx has secured NIH and DoD non-dilutive funding and recently attracted angel investor backing, indicating strong validation and potential for co-development or sponsored programs. Target biopharma CDMOs and contract manufacturers with hypoxia-focused capabilities for potential collaboration on manufacturing, regulatory milestones, and trial support.

Clinical Pipeline First-in-class oxygen therapeutic with multiple animal studies across seven indications and ongoing Phase Ib/II trials in stroke and oncology, plus plans for Phase IIa in COVID-19 related AHRF. This suggests opportunities to engage with hospitals, research networks, and payer conversations around treatment paradigms for hypoxia-driven diseases.

Manufacturing Footprint Expansion to a Tucson GMP production facility and a lean headcount indicate capacity for scalable manufacturing partnerships and fast-track supply arrangements for clinical and early commercial runs. Explore equipment vendors, fill/finish collaborators, and logistics providers aligned with small-to-mid scale biotech production.

Key Personnel Access Active leadership with co-founder recognition and an engaged scientific advisory board points to open channels for advisory collaborations, consultant roles, or speaking engagements. Leverage connections for strategic introductions to therapeutic area experts and clinical trial networks.

Funding & Growth Significant non-dilutive funding alongside a recent funding bridge and Series A activity signal runway and investor confidence. Use this to craft value propositions around accelerated timelines, risk-sharing programs, and potential licensing or co-development discussions with larger pharma players seeking hypoxia-targeted assets.